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Cellular signaling pathways are not isolated from each other but
are interconnected to form complex signaling networks. Cells
receive information from many different growth factor receptors
and from cell-matrix and cell-cell contacts. They must then inte-
grate this information to regulate diverse processes, such as
protein synthesis and cell growth, motility, cell architecture and
polarity, differentiation, and programmed cell death. The same
signaling molecules are used to control different processes
within different signaling complexes or at different intracellular
locations. Moreover, signaling pathways are subject to develop-
mental regulation and generate different outcomes in different
cell types; the activation of a signaling molecule may have dis-
tinct consequences, depending on the cellular context.
Understanding how these extraordinarily complex signaling net-
works function in vivo and how they are altered in cancer cells
represents a major intellectual challenge.
The ability of intracellular signaling networks to integrate
and distribute regulatory information requires that individual sig-
naling proteins must act as nodes, responding to multiple inputs
and regulating multiple effector outputs. One of the major
advances in the last decade has been the recognition that many
signaling proteins contain modular protein domains that medi-
ate protein-protein interactions. These interaction modules
serve to target signaling proteins to their substrates or to specif-
ic intracellular locations, to respond to posttranslational modifi-
cations, such as phosphorylation, acetylation and methylation,
and to link polypeptides into multiprotein signaling complexes
and pathways (Pawson and Nash, 2003). The same protein
modules can also mediate intramolecular interactions that regu-
late signaling function, and a frequent theme is that upstream
regulators may act by promoting or disrupting these intramolec-
ular interactions. Thus, to understand the overall architecture of
the signaling network, we will ultimately need to identify all of
these inter- and intramolecular interactions.
The intricacy of cellular signaling networks has major impli-
cations for our understanding of tumor cell behavior and for our
ability to use this knowledge for cancer therapy. Cell prolifera-
tion, motility, and survival are regulated by multiple pathways,
and the changes that occur in cancer cells are the result of mul-
tiple alterations in cellular signaling machinery. Cancer cells are
genetically unstable, undergo multiple genetic and epigenetic
changes, and continuously evolve in response to selective pres-
sures. Even if a mutationally activated pathway can be blocked
by an inhibitor, tumor cells may evade the inhibitor by activating
other pathways. Thus, even though early stage malignancies
may respond to a single inhibitor—the success of Gleevec (STI-
571) being a prime example—effective therapies for more
advanced malignancies may require combinations of signaling
inhibitors, or signaling inhibitors in conjunction with traditional
DNA-damaging chemotherapeutic reagents.
The complex architecture of signaling networks and the
consequences of this complexity for possible cancer therapeu-
tics were recurrent themes at the Beatson International
Conference on Cell Signaling and Cancer, held July 6–9, 2003
in Glasgow, Scotland. The meeting was sponsored by Cancer
Research UK and the Association for International Cancer
Research and was organized by the Beatson Institute for
Cancer Research. Some of the signaling pathways discussed at
the meeting are illustrated in Figure 1.
The roles of Src and FAK in cell motility and invasion
The cellular src gene was the first protooncogene to be discov-
ered in the vertebrate genome. In the last few years, there has
been increasing evidence that Src plays an important role in
tumor cell invasion, in particular through its interaction with FAK
(focal adhesion kinase). Src and FAK are nonreceptor tyrosine
kinases that are localized to cell-matrix adhesions and mediate
integrin signaling. Following integrin engagement, FAK under-
goes autophosphorylation at Tyr 397 and Src becomes recruit-
ed to activated FAK via an interaction between the SH2 domain
of Src and FAK pTyr397. Src then phosphorylates FAK at a
number of tyrosine residues, creating docking sites for SH2
domain-containing signaling proteins, such as the adaptor
Grb2. Genetic inactivation of Src family kinases or of FAK caus-
es defects in cell motility, associated with an inability to turnover
focal adhesions. In addition, Src and FAK are found in mem-
brane ruffles and in podosomes (also known as invadopodia),
dynamic protrusions that are prominent in certain cancer cells
and which are involved in the degradation of the extracellular
matrix. Both Src and FAK exhibit elevated expression in a num-
ber of different epithelial tumors, especially in invasive cancers.
These observations have provided circumstantial evidence for a
role of Src and FAK in tumor cell motility and invasion.
Margaret Frame (Beatson Institute, Glasgow) described the
use of several different model systems to study the role of FAK
in carcinogenesis. In the two-stage skin carcinogenesis model,
mouse skin is initially painted with dimethylbenzanthracene
(DMBA), which causes Ha-Ras mutations and the growth of
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papillomas. Subsequent treatment with the tumor promoter
tetradecanoyl phorbol acetate (TPA) causes progression of the
papillomas to malignant carcinomas. Experiments using fak
knockout heterozygotes or a conditional fak allele indicate that
the level of FAK protein appears to be a determinant of both ini-
tiation and progression. Reconstitution experiments with FAK−/−
fibroblasts and mutant forms of FAK suggested that tyrosine
phosphorylation of FAK is critical for cell motility. Moreover,
when activated Src was introduced into noninvasive colon can-
cer cells, they were converted from an epithelial to a more inva-
sive, mesenchymal phenotype, associated with a change from
cadherin-dependent cell contacts to integrin-dependent matrix
adhesions (Avizienyte et al., 2002).This alteration was also cor-
related with tyrosine phosphorylation of FAK. Thus, FAK activa-
tion and phosphorylation of FAK by Src appear to be important
determinants of tumor cell motility and invasiveness.
Another mechanism by which the interaction between Src
and FAK enhances tumor cell invasion was described by David
Schlaepfer (Scripps Institute, La Jolla, California). Trans-
formation of FAK null cells by v-Src yields transformants that are
noninvasive in Matrigel assays.The invasive properties of these
transformants were restored by reexpression of wild-type FAK
but not by reexpression of FAK mutated at the Src docking site
(Tyr397). Reconstitution experiments linked cell invasion to the
formation of a signaling complex involving Src, FAK, the docking
protein Cas, the adaptor Crk, and a guanine nucleotide
exchange factor, Dock180, which activates the small GTPase
Rac. Activation of Rac was shown in turn to activate the Jun-
kinase (JNK) cascade, which leads to the activation and secre-
tion of matrix metalloproteinases such as MMP-2 and MMP-9
(Hsia et al., 2003). Thus a Src-FAK-Rac pathway appears to
promote the invasiveness of Src-transformed cells. In addition,
although expression of FAK does not promote the growth of
Src-transformed cells in vitro, it does promote their growth as
tumors in vivo, and this is correlated with increased expression
of VEGF and increased tumor angiogenesis. Furthermore,
these effects of FAK are not restricted to cells transformed by
Src in vitro, because a dominant-negative form of FAK (FAK-
related non kinase or FRNK) blocks the growth of breast carci-
noma cells as tumors in vivo. Finally, FAK plays still other roles
in Src-induced focal adhesion turnover. Neil Carragher
(Beatson Institute, Glasgow) reported that the protease calpain
is activated in v-Src-transformed cells and that its recruitment to
focal adhesions promotes focal adhesion turnover and is
dependent on FAK (Carragher et al., 2002).
Another Src substrate, FISH, may also be involved in the
induction of cell invasion by activated Src. This adaptor protein
was identified by Sara Courtneidge (Van Andel Institute, Grand
Rapids, Michigan) and so named because it has five SH3
domains. The N terminus of FISH contains a PX domain that
targets tyrosine phosphorylated FISH to podosomes/invadopo-
dia. FISH in turn binds via one of its SH3 domains (SH3 #5) to
ADAMs family metalloproteinases, in particular ADAMs 12, 15,
and 19 (Abram et al., 2003). Thus Src appears to be involved in
the recruitment of FISH and associated metalloproteinases to
podosomes.
Yet other pathways are involved in morphological transfor-
mation by activated Src. Morphological transformation and
increased cell motility are generally associated with loss of
stress fibers. Stress fiber formation is induced by the small
GTPase RhoA. Since activated RhoA can suppress morpholog-
ical transformation by v-Src and since Src can activate the Rho
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Figure 1. Cellular signaling pathways involved in cancer
This figure illustrates some of the signaling pathways involved in malignant transformation and tumor cell proliferation that were discussed at the meeting.
Arrows (black) indicate activation or induction, T-bars (red) indicate inhibition. See text for details.
CANCER CELL : SEPTEMBER 2003 169
GTPase-activating protein p190RhoGAP, it had been suggest-
ed that Src decreases Rho activity. However, results from our
own laboratory communicated at the meeting reported that acti-
vated Src does not decrease the level of Rho[GTP] and can
actually increase Rho[GTP] levels (G.S.M., unpublished
results). RhoA promotes stress fiber formation in part via the
Rho-dependent kinase (ROCK)-LIM kinase pathway, which
results in the phosphorylation and inactivation of the actin-sev-
ering protein cofilin. As first reported by Pawlak and Helfman
(2002), Src transformation can result in the dephosphorylation
of cofilin. We reported that the kinase activity of Src activates a
MEK-independent pathway that results in dephosphorylation
and activation of cofilin.
Thus Src promotes cell motility and tumor cell growth by
multiple mechanisms. Many of these are dependent on FAK and
involve the local activation of Ras or Rac, or the recruitment of
calpain, while others, such as the phosphorylation of FISH and
the dephosphorylation of cofilin, may be FAK independent.
Clearly Src and FAK are promising targets for inhibitors of tumor
cell invasion.
The Ras/MAP kinase pathway:Targets and scaffolds
Ras is mutationally activated in a significant fraction of human
cancers. It interacts with multiple effectors, probably more than
twenty. One of these, the serine/threonine kinase Raf, activates
a MAP kinase pathway, the Raf-MEK-ERK pathway, which is
required for transformation by oncogenic Ras in a number of
systems. The ERK MAP kinases themselves have many sub-
strates, and the identity of these substrates and their roles in
tumorigenesis remain central questions.The pathway is regulat-
ed and organized by scaffolding proteins, in ways that are not
yet fully understood. Finally, as discussed at the end of this
report, components of this pathway are under intense investiga-
tion as possible targets for anti-cancer therapeutics.
The MAP kinase pathway activates Ets family transcription
factors that in turn regulate the expression of multiple genes,
including an ephrin receptor, the receptor-tyrosine kinase
EphA2 (Frank McCormick, University of California, San
Francisco). EphA2 activates p120RasGAP (Miao et al., 2001),
and so downregulates wild-type Ras but not mutationally acti-
vated Ras. Thus, EphA2 forms a component of a negative feed-
back loop, in which the Ras-MAP kinase pathway stimulates
EphA2 expression, which in turn downregulates Ras.
McCormick reported that breast cancer lines fall into two class-
es. More differentiated epithelial lines expressing wild-type Ras
also express the EGF-related receptor-tyrosine kinase ErbB3
and the EphA2 ligand ephrin, but do not express EphA2. The
reason that EphA2 is not expressed in this class of breast can-
cer cell is partly because there is selection against EphA2
expression (since this downregulates wild-type Ras) and partly
because ephrin itself downregulates EphA2. In contrast, the
second class of breast cancer lines are more invasive and mes-
enchymal in phenotype and express both EphA2 and, in some
cases, mutationally activated Ras. The invasive phenotype of
this second class can be decreased by expression of ephrin.
Activation of MAP kinase can exert antiapoptotic effects that
are important in tumor cell survival. Lindsey Allan (University of
Dundee) described a novel target of MAP kinase signaling, cas-
pase 9. This is a caspase that mediates mitochondrion-depen-
dent apoptosis by activating caspase 3 in response to
cytochrome c release. ERK MAP kinases phosphorylate cas-
pase 9 at Thr125, and this phosphorylation inhibits proteolytic
processing and activation of caspase 9. Okadaic acid, which
inhibits protein phosphatases 1 and 2A, allows the accumula-
tion of the phosphorylated form and also inhibits caspase 9 acti-
vation (Allan et al., 2003).Thus, MAP kinase phosphorylation of
caspase 9 may represent one of the events by which oncogenic
Ras promotes tumor cell survival.
The Raf-MEK-MAP kinase pathway is organized by a vari-
ety of scaffold proteins, including Ksr, MP1, and 14-3-3 proteins.
These scaffold proteins may regulate the activity of the pathway
(positively or negatively), localize its output, increase the effi-
ciency of signal transmission, or isolate the pathway from
crosstalk by other MAP kinase pathways.Two MAP kinase path-
way scaffolds were discussed. One of these, identified by Walter
Kolch (Beatson Institute, Glasgow), is termed the Raf kinase
inhibitor protein or RKIP. This protein negatively regulates the
pathway by blocking the interaction of Raf with MEK (Yeung et
al., 1999). However, RKIP is itself phosphorylated by MAP
kinase, reducing its affinity for Raf and causing its dissociation
from Raf in vitro and in vivo. This appears to result in a positive
feedback loop, in that MAP kinase activity inhibits an inhibitor of
the pathway, and Kolch proposed that this loop may function to
convert the pathway from a graded to a more switch-like
response. This represents another example of a phenomenon
that is common to a number of signaling systems, namely the
use of positive or double-negative feedback loops to create a
switch-like “bistable” system (Ferrell, 2002). As an inhibitor of
the Raf-MAP kinase pathway, RKIP may function as a tumor
suppressor, and indeed RKIP expression is downregulated in
metastatic breast and prostate cancers. Thus, this scaffold
appears to serve primarily a regulatory function. A different
function appears to be exerted by the protein p14, which was
described by David Teis (University of Innsbruck). This is an
endosomal protein that interacts with the MAP kinase scaffold
MP1, which in turn interacts with both MEK and ERK kinases.
p14 is required both for the endosomal localization of MAP
kinases and for their activation on endosomes in response to
EGF. It appears that the EGF receptor and Ras both traffic to
endosomes and can activate the MAP kinase cascade at this
intracellular site (Teis et al., 2002). Thus, p14 is an endosomal
adaptor for the MAP kinase scaffold MP1 and serves to localize
MAP kinase activation to endosomes in response to EGF. It will
be of interest to identify endosomal substrates of MAP kinase
and to determine whether the endosomally localized enzyme
has a distinct function.
PI 3-kinases and the regulation of cell growth, motility, and
survival
The lipid kinase phosphatidylinositol 3-kinase (PI 3-kinase)
generates 3′-phosphoinositides that recruit proteins containing
lipid-recognition domains (PH domains, FYVE domains) to the
membrane. PI 3-kinase signaling regulates cell growth, motility,
and survival. PTEN, a phosphatase that dephosphorylates 3′-
phosphoinositides, is a tumor suppressor, and the gene encod-
ing p110α, the catalytic subunit of a type IA PI 3-kinase, is
amplified in human cancers. Moreover, many downstream tar-
gets of PI 3-kinase signaling, such as the protein kinase Akt and
the translation initiation factor eIF4E, are transforming in cell
culture. These and other observations indicate that PI 3-kinase
signaling is important in tumorigenesis.
In recent years, there has been increasing interest in the
regulation of cell growth and cell size, stimulated in part by
genetic analyses in Drosophila. The 3′-phosphoinositide-
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dependent kinases PDK1 and Akt (also known as PKB) initiate
a kinase cascade that plays a key role in growth regulation.
PDK1 activates Akt by phosphorylation of a Thr residue in the
activation loop, although full activation requires phosphorylation
of a Ser in a C-terminal hydrophobic motif. Akt in turn activates
another kinase, the mammalian target of rapamycin, mTOR.
mTOR activates translation in two ways. It activates the riboso-
mal S6 protein kinase, which has been implicated in the
increased translation of 5′-terminal oligopyrimidine tract (TOP)
mRNAs that encode ribosomal proteins and other components
of the translational machinery. mTOR also inactivates 4EBP-1,
an inhibitor of the initiation factor eIF4E. In this way, PI 3-kinase
signaling regulates the translational machinery and thus cell
growth. Peter Vogt (Scripps Institute, La Jolla) described the
role of mTOR in transformation by avian sarcoma viruses
encoding activated and membrane targeted forms of PI 3-
kinase or Akt. Transformation by these viruses is inhibited by
rapamycin, indicating that mTOR activation is necessary for
transformation (Aoki et al., 2001). Akt and PI 3-kinase downreg-
ulate an RNA and DNA binding protein, the Y box binding pro-
tein YB-1. Overexpression of YB-1 produces resistance to
transformation by Akt, without affecting Akt-dependent phos-
phorylation of 4EBP-1.YB-1 inhibits both cap- and IRES-depen-
dent translation. A mutant of YB-1 that is defective in RNA
binding localizes to the nucleus, rather than the cytoplasm, and
does not block transformation. Taken together, these observa-
tions suggest that the ability of YB-1 to block transformation is
related to its ability to inhibit translation and that downregulation
of YB-1 represents one of the pathways responsible for the
transforming activity of Akt.
Recent observations indicate that mTOR is regulated by the
tuberous sclerosis proteins, hamartin (TSC-1) and tuberin
(TSC-2). The tuberous sclerosis proteins are so called because
they are growth inhibitors and tumor suppressors, and muta-
tions in the TSC-1 and TSC-2 genes cause tubers in the brain or
hardened (sclerotic) tumors in other organs. Ernst Hafen
(University of Zurich) described a genetic and biochemical
analysis of the relationship between TSC-1/2, TOR, and a small
GTPase named Rheb (Ras homolog enriched in brain) (Garami
et al., 2003; Stocker et al., 2003). Mutations in the Drosophila
Rheb gene inhibit growth, while overexpression of Rheb pro-
motes cell growth. Epistasis tests indicate that Rheb functions
downstream of TSC-1/2 and upstream of TOR and S6K. Indeed
it appears that TSC-1/2 are GTPase-activating proteins for
Rheb. So PI 3-kinase and Akt signaling appear to activate TOR
by inhibiting TSC-1/2 and thereby activating Rheb. If this is the
case, however, and inhibition of TSC1/2 mediates the effects of
PI 3-kinase signaling on growth, why do mutations in TSC-1/2
produce only tumors and overgrowths, while mutations in PTEN
also result in cancer susceptibility? A possible answer was pro-
vided by Richard Lamb (Institute of Cancer Research, London).
Loss of TSC-1/2 not only activates TOR and S6K signaling, but
also impairs PI 3-kinase signaling and Akt activation.This nega-
tive feedback loop is mediated in part by S6K phosphorylation
of the insulin receptor substrate IRS-1, which impairs its interac-
tion with receptor-tyrosine kinases, and in part by S6K- and
TOR-mediated inhibition of IRS-1 transcription. Thus in tuber-
ous sclerosis, loss of TSC1/2 leads to increased S6K and TOR
signaling and increased growth, but the IRS-1-mediated nega-
tive feedback loop decreases PI 3-kinase signaling, blocking
cancer development. These observations therefore provide an
explanation for the different effects of loss of TSC-1/2 and inac-
tivation of PTEN.
In addition to its effects on cell growth, the PI 3-kinase-Akt
pathway can also promote malignant progression by enhancing
survival signaling. The PI 3-kinase/Akt pathway promotes cell
survival by Akt-dependent activation of mTOR, Iκ-kinase (IKK)
and Mdm2, and by inactivation of pro-apoptotic Bcl-2 family
members such as Bax and Bad and of pro-apoptotic transcrip-
tion factors such as FKHR. Julian Downward (Cancer Research
UK London Laboratories) described the use of 14-3-3 proteins,
which bind to a motif closely related to the phosphorylated Akt
substrate motif, as affinity reagents to purify and identify novel
Akt substrates. One of the Akt substrates so identified is YAP, an
activator of the p53-related transcription factor p73. YAP
enhances p73-induced transcription of the pro-apoptotic Bax
protein, and Akt reverses this effect, apparently by inducing
cytoplasmic translocation of YAP. Another novel Akt substrate,
Mad3, was identified by two-dimensional PAGE analysis of
phosphoproteins recognized by an Akt substrate anti-phospho-
epitope antibody. Mad3 is a component of the Myc/Max/Mad
transcription network that inhibits Myc-dependent transcription.
Akt appears to promote Myc function by phosphorylating Mad3
and sequestering it away from the Myc partner, Max.
Paradoxically, Downward reported, PI 3-kinase and its down-
stream effector S6 kinase also mediate Ras-induced cellular
senescence, a phenomenon observed in primary cells that is
believed to act as a tumor suppressor mechanism. Thus, PI 3-
kinase signaling not only promotes tumor cell growth and sur-
vival but also elicits this protective checkpoint mechanism.
PI 3-kinase signaling also regulates cell motility and the
actin cytoskeleton. A PtdIns(3,4,5)P3 binding protein which may
mediate some of these effects was described by Len Stephens
(Babraham Institute, Cambridge). This protein, ARAP3, was
identified by virtue of its ability to bind to matrices carrying 3′-
phosphoinositides (Krugmann et al., 2002). ARAP3 has five PH
domains, of which one is required for translocation to mem-
brane ruffles following PDGF treatment. Overexpression or
RNAi knockdown of ARAP3 results in changes in cell spreading
and in the ruffling response to PDGF, suggesting that ARAP3
plays some role in the regulation of the actin cytoskeleton by 3′-
phosphoinositides. ARAP3 contains a 3′-phosphoinositide-
stimulated GAP domain that is specific for Arf6, a small GTPase
involved in delivery of an endosomal compartment to the lamel-
lipodium, and the Arf6 GAP activity of ARAP3 blocks Arf6 trans-
port to the cell surface. ARAP3 also contains a Rho GAP
domain, which is stimulated by the Ras-related GTPase, Rap.
Both Arf GAP and Rho GAP domains are required to mediate PI
3-kinase-dependent rearrangements in the actin cytoskeleton
and cell shape. Thus, the GAP domains of ARAP3 appear to
transduce signals from PI 3-kinase to the actin cytoskeleton and
cellular trafficking machinery.
Although it is convenient to refer to PI 3-kinase activity
generically as though it were a single enzyme, there are multi-
ple isoforms of PI 3-kinase, differing in modes of regulation and
pattern of expression. Class IA PI 3-kinases are regulated by
recruitment to tyrosine-phosphorylated receptors or docking
proteins and by direct interaction of the catalytic subunit with
small GTPases such as Ras, while class IB PI 3-kinases are
regulated by the Gβγ subunits of heterotrimeric G proteins. The
class IA PI 3-kinases contain one of three catalytic subunits
(p110α, p110β, and p110δ), plus one of five SH2 domain-con-
taining regulatory subunits. Do these different isoforms have
specific signaling mechanisms or physiological functions?
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Attempts to answer this question with knockout mice have been
bedeviled by compensatory changes in the remaining isoforms.
Bart Vanhaesebroeck (Ludwig Institute, London) described the
generation of knockin mutations that render the molecule cat-
alytically inactive and the use of these mutants to study isoform-
specific function (Okkenhaug and Vanhaesebroeck, 2003).
Whereas p110δ-deficient mice are viable but display defects in
T and B cell signaling, p110α-deficient mice exhibit embryonic
lethality at E10–11, and p110α-deficient fibroblasts do not pro-
liferate. These results imply that PI 3-kinases have isoform-spe-
cific functions; since they all carry out the same catalytic
function, perhaps they interact with different regulators or func-
tion at different intracellular locations. It will be important to
determine whether different isoforms play different roles in dif-
ferent cancers.
Activators and effectors of Rho family GTPases
In normal cells, Rho family GTPases regulate cell motility and
proliferation. The levels of various Rho family members are ele-
vated in different cancers, and Rho, Rac, and Cdc42 are
required for transformation by Ras. However, whereas in human
cancers Ras is activated primarily by mutations that block GTP
hydrolysis, Rho family members are activated by changes in
upstream regulators. Indeed, Rho family GEFs are oncogenes
in vitro. RhoGEFS have Dbl homology (DH) domains paired with
adjacent PH domains, plus additional protein modules that link
the GEFs to upstream signals. For example, as Channing Der
(University of North Carolina at Chapel Hill) described, the Rac
GEF Tiam1 contains a Ras binding domain. Tiam1-deficient
mice are resistant to Ras-induced Rac activation and to Ras-ini-
tiated tumorigenesis (Lambert et al., 2002; Malliri et al., 2002).
Moreover the anchorage-independent growth of pancreatic
cancer cells carrying activated (G12V) K-Ras is dependent on
the continued expression of both activated Ras and Tiam1.
Thus, Ras transformation appears to be dependent on Tiam1-
mediated activation of Rac. Another example of Rho-dependent
transformation is provided by the seven-transmembrane G pro-
tein-coupled thrombin receptor, PAR1. PAR1 is an oncogene
when overexpressed, and this transforming capacity is depen-
dent on RhoA function. PAR1 internalization and degradation is
impaired in invasive breast cancer cells, and antisense knock-
down experiments indicate that the invasiveness of breast car-
cinoma lines is dependent on PAR1 function. PAR1-mediated
invasion is dependent on Gαi (which activates Ras) and
Gα12/13 (which activate RhoA). Thus, the activation of Rac in
pancreatic cancers and the activation of Rho in breast cancers
are both due to changes in upstream signaling.
Both integrin signaling and growth factor signaling are
required for the proliferation of anchorage-dependent cells. One
of the mechanisms by which integrin and growth factor signaling
are coordinated is through the adhesion-dependent targeting of
Rac to the membrane (del Pozo et al., 2000 #16). Martin
Schwartz (Scripps Institute, La Jolla) described a mechanism
by which integrin signaling modulates lipid rafts and caveolae at
the plasma membrane, and as a consquence, Rac activity.
The multiplicity of biological effects of Rho family GTPases
is reflected in the multiplicity of effectors with which they inter-
act. Actin stress fiber assembly driven by RhoA is mediated by
two primary RhoA targets. One class, the Diaphanous-related
formins, promote the polymerization of actin filaments and
microtubules and are discussed below.The other class, the Rho
kinases (ROCKs), promote actomyosin contraction by enhanc-
ing myosin light chain phosphorylation and, as noted earlier,
promote actin filament stability by inactivating the actin filament-
severing protein cofilin. Chris Marshall (Institute of Cancer
Research, London) reported that tumor cells exhibit two distinct
modes of cell motility that differ in their requirement for Rho sig-
naling through ROCK. The first mode of cell motility is the “clas-
sic” lamellipodial or mesenchymal motility driven by active Rac.
This mode of motility requires downregulation of Rho-ROCK
signaling. One way in which this can occur, as noted earlier for
Src-transformed cells, is by dephosphorylation of cofilin. In cells
transformed by activated Ras, downregulation of Rho-ROCK
signaling is dependent on ERK MAP kinase activity (Vial et al.,
2003). ERK activates the transcription and translation of the AP-
1 component Fra-1, which inactivates integrin β1 signaling and
thus downregulates RhoA. At the same time, ERK signaling
upregulates the expression of uPAR (the receptor for urokinase
plasminogen activator), which in turn activates Rac. In contrast
to this lamellipodial, Rac-dependent type of movement, howev-
er, the invasiveness of some tumor cell types is actually depen-
dent on Rho-ROCK signaling (Sahai and Marshall, 2003).
These cells have a rounded “blebby” morphology and a polar-
ized distribution of ezrin, and their ability to invade is indepen-
dent of matrix metalloproteinase secretion. Some tumor cell
types exhibit both the mesenchymal, protease-dependent mode
of invasion and the protease-independent, Rho-ROCK-depen-
dent mode of cell movement. In these instances, inhibition of
both proteases and ROCK is required to block cell motility. This
suggests that an effective therapeutic strategy to inhibit tumor
cell metastasis might be to simultaneously target both matrix
metalloproteinases and ROCK.
The Diaphanous-related formins, which function as active
scaffolds that direct actin filament and microtubule assembly,
represent another major class of effectors for Rho family
GTPases (Waller and Albert, 2003). They are characterized by
the presence of formin homology (FH) domains and regulatory
domains thought to confer sensitivity to active Rho GTPases: an
amino-terminal GTPase binding domain (GBD) and a carboxy-
terminal Dia-autoregulatory domain (DAD). Interaction of the
GBD with the cognate GTPase disrupts the intramolecular
GBD-DAD interaction and promotes the scaffolding function of
the protein. Different formins appear to interact with distinct
spectra of GTPases, suggesting that different GTPase-formin
pairs are functionally distinct. To approach this question, Art
Alberts (Van Andel Institute, Grand Rapids, Michigan) has used
FRET (fluorescence resonance energy transfer) to analyze the
sites of formin-GTPase interactions in intact cells. In one exam-
ple, Cdc42 specifically interacts with mDia2 at the leading edge
and MTOC of cells migrating into a wound. Demonstrating an
effector role for mDia2, blocking mDia2 function inhibits the gen-
eration of filopodia induced by activated Cdc42. To explain
these observations, Alberts proposed a model in which Cdc42
activates mDia2 at the base of the nascent filopodium and thus
stimulates actin filament assembly and filament protrusion at
the leading edge of migrating cells. In contrast to Cdc42, FRET
analyses indicate that RhoB interacts with mDia2 on endo-
somes and RhoA interacts with mDia2 across the plasma mem-
brane. Despite their ability to interact in vitro, mDia2 and RhoC
did not interact in intact cells, suggesting that cells confer an
additional specificity on GTPase-formin pairs. In another exam-
ple, another formin protein (FHOD1) binds Rac in vitro and in
vivo interacts with Rac on ruffles. Though recent studies have
shown that formins nucleate nonbranched actin filaments in
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vitro, it appears that different formins participate in the formation
of different cytoskeletal structures at discrete sites and in
response to different GTPases. Surprisingly, however, it
appears that the GTPase binding domain is not itself required
for subcellular targeting.Thus, rather than the GTPase targeting
the formin to the site at which it functions, it may be that formin
localization precedes the activation of the GTPase. This is a dif-
ferent model than the general paradigm for small GTPase func-
tion, in which the GTPase is responsible for recruiting its
effectors to their site of function.
The WAVE/Scar proteins (WAVE-1, -2, and -3 in mammals)
represent another class of scaffolding protein that mediates the
effects of Rho family GTPases on the actin cytoskeleton. These
proteins link Rho family GTPases to the Arp2/3 complex, which
nucleates actin filament assembly and actin filament branching.
Rac promotes WAVE-1 activation, and signaling by Rac is termi-
nated by a WAVE-1-associated GTPase-activating protein
named WRP. John Scott (Vollum Institute, Oregon Health and
Sciences University, Portland) described the properties of
WAVE-1 knockout mice (Soderling et al., 2003). These animals
are viable but exhibit a variety of sensorimotor and learning
deficits that are remarkably similar to those associated with
haploinsufficiency of WRP in humans. Thus, alterations in Rac-
regulated actin filament assembly may underlie this form of
mental retardation.
Expression of activated Rho family GTPases has global
effects on gene expression and function. Natalie Ahn (University
of Colorado, Boulder) described a functional proteomics
approach to characterize these changes. Cells expressing acti-
vated mutants of RhoA, Cdc42, or Rac1 were analyzed by 2D-
PAGE and spots identified by MALDI-qTOF peptide mass
sequencing and peptide sequencing. The expression of some
proteins was uniquely regulated by one specific GTPase,
whereas others were regulated by more than one GTPase. The
2D-PAGE analysis also revealed covalent modifications induced
by specific GTPases. For example, RhoA was found to inhibit
PTP1B and thereby promote the phosphorylation of p130Cas.
Since Cas phosphorylation promotes cell motility, it is conceiv-
able that a Rho-PTP1B-Cas pathway might be involved in the
Rho-dependent type of motility described earlier.
Novel and atypical protein kinase Cs in cell-matrix interac-
tions and the control of cell polarity
Conventional isoforms of protein kinase C (cPKCs: α, β, and γ)
are dependent on phospholipids, particularly phosphatidylser-
ine, Ca2+, and diacylglycerol. They have been the focus of
intense interest since the discovery that they are targeted by
tumor promoters such as TPA. The more recently identified
novel PKCs (nPKCs: δ, ε, η, and θ) are dependent only on phos-
pholipids and diacylglycerol, while the atypical PKCs (aPKCs:
ι/λ and ζ) are dependent only on phospholipids. It now appears
that the novel and atypical PKCs play critical roles in the
response to cell-cell and cell-matrix interactions and in the
development of cell polarity. Peter Parker (Cancer Research UK
London Research Institute) described how the novel PKC PKCε
integrates integrin and cytokine signaling (Ivaska et al., 2003).
Integrin engagement regulates the formation of a complex
between PKCε, protein phosphatase 2A, and PDK1, such that
PKCε is fully phosphorylated and active only in attached cells.
PKCε activity in turn regulates interferon γ-induced phosphory-
lation of STAT1 by Janus kinases (Jak1, Jak2) so that the inter-
feron-γ pathway is only active in attached cells. In this way,
PKCε acts as a signal integrator mediating integrin regulation of
cytokine responses.
The atypical PKCs appear to play an important role in the
response to cell polarity signals. As first demonstrated by genet-
ic studies on asymmetric division in C. elegans, one of the major
determinants of cell polarity is a complex of the GTPase Cdc42,
an atypical PKC and two scaffolding proteins, Par3 and Par6.
Tony Pawson (Samuel Lunenfeld Research Institute, Toronto)
described how a series of interactions assemble this complex at
tight junctions between epithelial cells and at the leading edge
of migrating astrocytes. In mammalian cells, there are direct
interactions between aPKC, Par6, and mLgl, the mammalian
homolog of the Drosophila tumor suppressor Lethal (2) giant
larvae (Plant et al., 2003). mLgl contains aPKC phosphorylation
sites that are important for fibroblasts to polarize in response to
wounding. Thus, aPKC is directed to its substrate by specific
protein-protein interactions. These interactions are part of a
much larger network of interactions that connect the Par3-Par6
cell polarity complex to other complexes that regulate cell polar-
ity, vesicle trafficking, microtubule stability, cell junction forma-
tion, and cell proliferation.
Signaling inhibitors as cancer therapeutics
Transformation of fibroblasts by activated oncogenes such as
Ras is dependent on multiple pathways, and in some instances,
inhibition of a single one of these pathways can inhibit transfor-
mation. If this is a valid model for carcinogenesis, single signal-
ing inhibitors might be effective cancer therapeutics. However
there are also precedents for believing that effective inhibition of
some aspects of transformation may require multiple inhibitors.
The synergy between metalloproteinase inhibitors and ROCK
inhibitors in inhibiting tumor cell invasion, as described by Chris
Marshall (see above), represents one such precedent.
Moreover, as argued earlier, because tumor cells are genetical-
ly unstable and continually evolving, they may be able to evade
blockade of a single pathway so that effective therapies may
require the use of multiple inhibitors, or the use of signaling
inhibitors as supplements to therapy with conventional DNA-
damaging agents.
Raf proteins are under active investigation as therapeutic
targets. There are three isoforms of Raf in mammals, Raf-1, B-
Raf, and A-Raf. Mutations in the activation loop of B-Raf that
activate catalytic activity have recently been found to occur in
some 66% of melanomas and at a lower frequency in other can-
cers (Davies et al., 2002). The most common mutation is
V599E, and this mutant form of Raf is transforming for NIH-3T3
cells. Maria Karasarides (Institute of Cancer Research, Landon)
reported that transformation can be blocked by RNAi downregu-
lation of B-Raf or by MEK inhibitors. Furthermore, downregula-
tion of B-Raf in melanoma cells results in caspase 3 activation
and apoptosis. Frank McCormick (University of California, San
Francisco) discussed the therapeutic potential of a Raf inhibitor
developed at the Bayer Corporation. Starting with a lead struc-
ture with an IC50 for Raf inhibition of 17 µM, the Bayer group,
using combinatorial chemistry, developed an orally active com-
pound, BAY 43-9006, which has an IC50 for Raf inhibition of 12
nM.This inhibitor blocks MEK phosphorylation by mutant B-Raf.
Phase I trials suggest that the inhibitor may induce a partial
response or stabilize disease progression when administered
as single agent in the treatment of renal cell carcinoma or when
used in combination with carboplatin and paclitaxel for the treat-
ment of melanomas. These exciting but still preliminary findings
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suggest that Raf activity is a promising target for therapeutic
intervention.
STI-571 (Gleevec) has proven extremely effective in the
treatment of chronic myelogenous leukemia, in which Abl is
activated by translocation, and is also effective in the treatment
of gastrointestinal stromal tumors, in which there are mutations
in either c-Kit or the PDGF receptor α. Carl-Henrik Heldin
(Ludwig Institute for Cancer Research, Uppsala, Sweden)
described other uses of STI-571 as a PDGF receptor antagonist
(Pietras et al., 2003). One such use is in the treatment of der-
matofibrosarcoma protuberans, a disease of intermediate
malignancy. It results from a fusion of the collagen1A1 gene to
the gene encoding the PDGF-B chain: the fusion gene product
is processed to generate PDGF-B chain. STI-571 reduces the
growth of subcutaneous dermatofibrosarcoma tumors in a
xenograft model. Clinical trials suggest that STI-571 can induce
tumor regression. Another use of STI-571 as a cancer thera-
peutic stems from its effect on tumor stromal cells, which fre-
quently express PDGF receptors. Activation of stromal PDGF-R
causes an increase in tumor interstitial fluid pressure, which
reduces the uptake of chemotherapeutic drugs. Heldin demon-
strated that STI-571 reduces tumor interstitial fluid pressure and
thereby increases the uptake and efficacy of drugs such as
taxol and 5-FU (Pietras et al., 2002).
The response of a tumor cell to an inhibitor or drug depends
on its particular genetic and epigenetic status. Tumor cells
acquire resistance to apoptosis during the course of tumor pro-
gression, and enhanced survival signaling may be important in
promoting resistance to chemotherapeutic agents (Johnstone
et al., 2002). For example, Scott Lowe (Cold Spring Harbor
Laboratory, New York) reported that the introduction of various
antiapoptotic lesions (e.g., p53 loss, or overexpression of Bcl-2
or Akt) in Eµ-Myc transgenic mice enhances lymphomagenesis
and the chemoresistance of the lymphomas. Interestingly, the
nature of the antiapoptotic lesion can have an impact on how
the lymphoma responds to a combination of conventional and
targeted agents. Thus, knowledge of apoptosis resistance
mechanisms in cancer may allow the tailoring of therapies for
individual patients. With this in mind, Lowe described the use of
short-hairpin RNA libraries to identify genes that either sensi-
tize or inhibit drug-induced apoptosis. In the same context,
Margaret Frame and Caroline Dive (University of Manchester)
reported that catalytically inactive mutants of Src sensitize
metastatic colon cancer cells to oxaliplatin- and Fas-induced
apoptosis. These src mutants might act as either adaptor pro-
teins or dominant-negatives and might either inhibit an antiapo-
ptotic pathway or promote a proapoptotic pathway.
The findings described at this meeting indicate that our
understanding of signaling pathways has advanced to the point
where specific targets for therapeutic intervention can be identi-
fied. However, we need to understand how whole signaling net-
works function within the context of the intact cell if we are to
develop rational strategies based on the genetic alterations of
individual cancers. Based on the pace of the progress reported
at this meeting, it is safe to predict that the next few years
should see exciting new developments in targeted cancer
therapies.
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